RP5063 (brilaroxazine) is a late-stage investigational CNS drug candidate in development for schizophrenia. Company updates describe it as a novel serotonin-dopamine and neuroinflammatory signaling modulator, with a completed Phase 3 program and planned RECOVER-2 Phase 3 trial following FDA pre-NDA feedback. It is not yet approved for marketing.
The bipolar depression treatment pipeline includes over 10 therapies from 8+ companies, with recent Phase 3 trials initiated for azetukalner and multiple emerging drugs targeting novel pathways expected to launch by 2036.
Researchers identify speech latency as a biomarker to enrich schizophrenia clinical trials, while a separate study finds clozapine more effective than alternatives for patients who fail initial antipsychotic treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01490086 |
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder |
COMPLETED | PHASE2 |
